SHANGHAI (AFP) - Chinese state television put two foreign fraud investigators on display on Tuesday as police announced they had been charged with illegally obtaining personal information.
Police in Shanghai arrested British national Peter Humphrey and his wife Yu Yingzeng, an American citizen, the Ministry of Public Security said in a statement.
They are accused of obtaining personal information and selling reports for "high prices" to clients, it added.
The statement did not mention work their firm did for GlaxoSmithKline (GSK), following speculation their detention might be related to the British pharmaceutical giant, which is facing a bribery investigation in China.
In a report which appeared to be coordinated with the police announcement, China Central Television showed Humphrey walking in handcuffs and wearing the orange vest of a Shanghai detention centre.
Yu was also shown, though both of their faces were deliberately blurred.
"I deeply regret this matter and I apologise to the Chinese government," Humphrey said in the report.
Yu told state radio that their clients were multinational companies including manufacturers, financial institutions and law firms. No names were given.
Humphrey, a veteran fraud investigator and former journalist for the news agency Reuters, is the founder of Shanghai-based risk advisory firm ChinaWhys, while Yu worked as its general manager.
Police said the firm collected, bought or used other methods to obtain information about Chinese citizens including addresses, family members, travel, property and car ownership.
Of more than 500 investigative reports, "more than 10" had been found to violate the privacy of Chinese citizens, the statement said.
Police said the firm paid 800 yuan to 2,000 yuan (S$165-414) for each piece of information, China National Radio reported.
Diplomats last week confirmed the formal arrest of the pair after several weeks of detention.
Chinese authorities have detained four GSK executives for allegedly masterminding a scheme to funnel bribes to doctors in return for buying the pharmaceutical firm's products.
GSK has admitted some of its executives violated Chinese law and pledged to cooperate with the investigation into it, which comes amid a broader government probe of foreign pharmaceutical firms operating in China.
